Find Propofol manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

PATENTS & EXCLUSIVITIES

0

US Exclusivities

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

12 RELATED EXCIPIENT COMPANIES

21EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 2,6-diisopropylphenol, 2078-54-8, Diprivan, Disoprofol, Disoprivan, Fresofol
Molecular Formula
C12H18O
Molecular Weight
178.27  g/mol
InChI Key
OLBCVFGFOZPWHH-UHFFFAOYSA-N
FDA UNII
YI7VU623SF

Propofol
An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.
Propofol is a General Anesthetic. The physiologic effect of propofol is by means of General Anesthesia.
1 2D Structure

Propofol

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2,6-di(propan-2-yl)phenol
2.1.2 InChI
InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3
2.1.3 InChI Key
OLBCVFGFOZPWHH-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(C)C1=C(C(=CC=C1)C(C)C)O
2.2 Other Identifiers
2.2.1 UNII
YI7VU623SF
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2,6 Diisopropylphenol

2. 2,6-bis(1-methylethyl)phenol

3. 2,6-diisopropylphenol

4. Aquafol

5. Diprivan

6. Disoprivan

7. Disoprofol

8. Fresofol

9. Ici 35,868

10. Ici 35868

11. Ici-35,868

12. Ici-35868

13. Ici35,868

14. Ici35868

15. Ivofol

16. Propofol Abbott

17. Propofol Fresenius

18. Propofol Mct

19. Propofol Rovi

20. Propofol-lipuro

21. Recofol

2.3.2 Depositor-Supplied Synonyms

1. 2,6-diisopropylphenol

2. 2078-54-8

3. Diprivan

4. Disoprofol

5. Disoprivan

6. Fresofol

7. Diisopropylphenol

8. 2,6-bis(1-methylethyl)phenol

9. Ampofol

10. Rapinovet

11. Phenol, 2,6-bis(1-methylethyl)-

12. 2,6-di(propan-2-yl)phenol

13. Propofolum

14. Recofol

15. Ivofol

16. Propofol-lipuro

17. Pofol

18. Ici 35868

19. 2,6-diisopropyl Phenol

20. Diprifusor

21. Diprofol

22. Propovan

23. Phenol, 2,6-diisopropyl-

24. Diprivan 10

25. Ici-35868

26. Lipuro

27. Nsc 5105

28. Ici 35,868

29. 2,6-bis(propan-2-yl)phenol

30. 2,6-diisopropyl-phenol

31. Ici35,868

32. Mfcd00008885

33. Chembl526

34. Yi7vu623sf

35. Chebi:44915

36. Nsc5105

37. 2,6-di-iso-propylphenol-d18

38. Phenol, 2,6-bis(1-methylethyl)

39. Nsc-5105

40. Ici 35-868

41. Propofolum [latin]

42. Ncgc00015389-08

43. Aquafol

44. Cas-2078-54-8

45. Dsstox_cid_3523

46. Dsstox_rid_77063

47. Dsstox_gsid_23523

48. Diprivan Injectable Emulsion

49. 2,6 Diisopropylphenol

50. Dipravan

51. Propoven

52. Aquafo

53. Propofol Idd-d

54. Diprivan (tn)

55. Smr000059151

56. Ccris 9000

57. Propofol(2,6-diisopropylphenol)

58. Hsdb 7123

59. 2, 6-diisopropylphenol

60. Sr-01000075468

61. Einecs 218-206-6

62. 2,6-bis(isopropyl)phenol

63. Unii-yi7vu623sf

64. Brn 1866484

65. Dds-04f

66. Ghl.pd_mitscher_leg0.558

67. Ai3-26295

68. Propofol Solution

69. Propofol [usan:usp:inn:ban]

70. Propofol (diprivan)

71. Zd-0859

72. Phenol,6-diisopropyl-

73. Propofol [hsdb]

74. Propofol [usan]

75. Propofol [inn]

76. Propofol [jan]

77. Propofol [mi]

78. Propofol [vandf]

79. Prestwick0_000931

80. Prestwick1_000931

81. Prestwick2_000931

82. Prestwick3_000931

83. 2,6-di Isopropyl Phenol

84. Propofol [mart.]

85. 2,6-dipropan-2-ylphenol

86. Biomol-nt_000248

87. Lopac-d126608

88. Propofol [usp-rs]

89. Propofol [who-dd]

90. Diisopropylphenol (related)

91. Propofol (jan/usp/inn)

92. Lopac0_000437

93. Schembl36245

94. Bspbio_000862

95. 4-06-00-03435 (beilstein Handbook Reference)

96. Mls001066348

97. Mls001335999

98. Mls002454360

99. Bidd:gt0436

100. Propofol [green Book]

101. Spectrum1505022

102. Spbio_003031

103. 2,6-diisopropylphenol, 97%

104. Propofol [ep Impurity]

105. Propofol [orange Book]

106. Bpbio1_000950

107. Bpbio1_000969

108. Gtpl5464

109. Phenol,6-bis(1-methylethyl)-

110. Propofol [ep Monograph]

111. Propofol [usp Impurity]

112. Dtxsid6023523

113. Propofol [usp Monograph]

114. Ketafol Component Propofol

115. Propofol 1.0 Mg/ml In Methanol

116. 2,6-diisopropylphenol, >=97%

117. 3f33

118. 3p50

119. Hms1570l04

120. Hms2089o21

121. Hms2094e17

122. Hms2097l04

123. Hms2231e16

124. Hms3259e03

125. Hms3261g16

126. Hms3369i16

127. Hms3714l04

128. Pharmakon1600-01505022

129. Zinc968303

130. Albb-036351

131. Bcp02920

132. Hy-b0649

133. Tox21_110134

134. Tox21_201371

135. Tox21_303225

136. Tox21_500437

137. Ac8633

138. Bdbm50058046

139. Nsc758909

140. Phenol, 2, 6-bis(1-methylethyl)-

141. Akos009159417

142. Tox21_110134_1

143. Ac-2038

144. Am90311

145. Ccg-204529

146. Cs-w020057

147. Db00818

148. Lp00437

149. Nc00449

150. Nsc-758909

151. Sdccgmls-0318084.p029

152. Sdccgsbi-0050422.p002

153. 2,6-diisopropylphenol; Propofol

154. Mls-0318084

155. Ncgc00015389-01

156. Ncgc00015389-02

157. Ncgc00015389-03

158. Ncgc00015389-04

159. Ncgc00015389-05

160. Ncgc00015389-06

161. Ncgc00015389-07

162. Ncgc00015389-09

163. Ncgc00015389-10

164. Ncgc00015389-11

165. Ncgc00015389-14

166. Ncgc00015389-17

167. Ncgc00091538-01

168. Ncgc00091538-02

169. Ncgc00091538-03

170. Ncgc00091538-04

171. Ncgc00091538-05

172. Ncgc00091538-06

173. Ncgc00257228-01

174. Ncgc00260670-01

175. Ncgc00261122-01

176. As-13299

177. Sy013479

178. 2,6-diisopropylphenol, Analytical Standard

179. Bcp0726000298

180. Mls-0318084.p017

181. Ab00513968

182. D0617

183. Eu-0100437

184. C07523

185. D00549

186. Ab00513968-07

187. Ab00513968_08

188. A814898

189. D126608

190. Q422740

191. Q-201631

192. Sr-01000075468-1

193. Sr-01000075468-4

194. Sr-01000075468-6

195. Brd-k82255054-001-03-5

196. Brd-k82255054-001-08-4

197. Propofol, British Pharmacopoeia (bp) Reference Standard

198. Propofol, European Pharmacopoeia (ep) Reference Standard

199. Z1245735300

200. Propofol, United States Pharmacopeia (usp) Reference Standard

201. Propofol, Pharmaceutical Secondary Standard; Certified Reference Material

202. Propofol For Peak Identification, European Pharmacopoeia (ep) Reference Standard

203. Propofol Solution, 1.0 Mg/ml In Methanol, Ampule Of 1 Ml, Certified Reference Material

204. 113981-41-2

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 178.27 g/mol
Molecular Formula C12H18O
XLogP33.8
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count1
Rotatable Bond Count2
Exact Mass178.135765193 g/mol
Monoisotopic Mass178.135765193 g/mol
Topological Polar Surface Area20.2 Ų
Heavy Atom Count13
Formal Charge0
Complexity135
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 4  
Drug NameDiprivan
PubMed HealthPropofol (Injection)
Drug ClassesSedative-Hypnotic
Drug LabelFor IV Administration OnlyRx OnlyStrict aseptic technique must always be maintained during handling. Diprivan Injectable Emulsion is a single-use parenteral product which contains 0.005% disodium edetate to inhibit the rate of growth of microorgani...
Active IngredientPropofol
Dosage FormInjectable
RouteInjection
Strength10mg/ml
Market StatusPrescription
CompanyFresenius Kabi Usa

2 of 4  
Drug NamePropofol
PubMed HealthPropofol (Injection)
Drug ClassesSedative-Hypnotic
Drug LabelPropofol injectable emulsion is a sterile, nonpyrogenic emulsion containing 10 mg/mL of propofol suitable for intravenous administration. Propofol is chemically described as 2,6-diisopropylphenol and has a molecular weight of 178.27. The structural a...
Active IngredientPropofol
Dosage FormInjectable
Routeinjection; Injection
Strength10mg/ml
Market StatusTentative Approval; Prescription
CompanyHospira; Teva Pharms Usa; Gensia Sicor Pharms; Baxter Hlthcare; Esi Lederle

3 of 4  
Drug NameDiprivan
PubMed HealthPropofol (Injection)
Drug ClassesSedative-Hypnotic
Drug LabelFor IV Administration OnlyRx OnlyStrict aseptic technique must always be maintained during handling. Diprivan Injectable Emulsion is a single-use parenteral product which contains 0.005% disodium edetate to inhibit the rate of growth of microorgani...
Active IngredientPropofol
Dosage FormInjectable
RouteInjection
Strength10mg/ml
Market StatusPrescription
CompanyFresenius Kabi Usa

4 of 4  
Drug NamePropofol
PubMed HealthPropofol (Injection)
Drug ClassesSedative-Hypnotic
Drug LabelPropofol injectable emulsion is a sterile, nonpyrogenic emulsion containing 10 mg/mL of propofol suitable for intravenous administration. Propofol is chemically described as 2,6-diisopropylphenol and has a molecular weight of 178.27. The structural a...
Active IngredientPropofol
Dosage FormInjectable
Routeinjection; Injection
Strength10mg/ml
Market StatusTentative Approval; Prescription
CompanyHospira; Teva Pharms Usa; Gensia Sicor Pharms; Baxter Hlthcare; Esi Lederle

4.2 Therapeutic Uses

Propofol is indicated for the induction of general anesthesia. It is also indicated for the maintenance of anesthesia utilizing balanced techniques with other appropriate agents such as opioids and inhalation anesthetics.

MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 2466


Propofol is indicated for the sedation in critically ill patients confined to intensive care units.

MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 2466


Propofol has successfully controlled seizures in status epilepticus.

Ellenhorn, M.J., S. Schonwald, G. Ordog, J. Wasserberger. Ellenhorn's Medical Toxicology: Diagnosis and Treatment of Human Poisoning. 2nd ed. Baltimore, MD: Williams and Wilkins, 1997., p. 1181


Propofol appears to have significant antiemetic action and is a good choice for sedation or anesthesia in patients at high risk for nausea and vomiting.

Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 345


4.3 Drug Warning

Compromised cardiovascular function may be aggravated by cardiovascular-depressant and hypotensive effects.

MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 2467


Caution is also recommended in geriatric, debilitated, and/or hypovolemic patients, because they may require lower induction and maintenance doses.

MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 2468


Substantial decreases in mean arterial pressure and cerebral perfusion may occur in patients with existing impaired cerebral circulation or increased intracranial pressure.

MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 2468


Rarely, a clinical syndrome including bronchospasm, erythema, and hypotension has occured shortly after administration of propofol, and sequelae including anoxic brain damage and death have been reported. /SRP: May be from metabisulfite./

MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 2468


For more Drug Warnings (Complete) data for PROPOFOL (17 total), please visit the HSDB record page.


4.4 Drug Indication

Used for induction and/or maintenance of anaesthesia and for management of refractory status epilepticus.


FDA Label


5 Pharmacology and Biochemistry
5.1 Pharmacology

Propofol is a sedative-hypnotic agent for use in the induction and maintenance of anesthesia or sedation. Intravenous injection of a therapeutic dose of propofol produces hypnosis rapidly with minimal excitation, usually within 40 seconds from the start of an injection (the time for one arm-brain circulation).


5.2 MeSH Pharmacological Classification

Anesthetics, Intravenous

Ultrashort-acting anesthetics that are used for induction. Loss of consciousness is rapid and induction is pleasant, but there is no muscle relaxation and reflexes frequently are not reduced adequately. Repeated administration results in accumulation and prolongs the recovery time. Since these agents have little if any analgesic activity, they are seldom used alone except in brief minor procedures. (From AMA Drug Evaluations Annual, 1994, p174) (See all compounds classified as Anesthetics, Intravenous.)


Hypnotics and Sedatives

Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
PROPOFOL
5.3.2 FDA UNII
YI7VU623SF
5.3.3 Pharmacological Classes
General Anesthetic [EPC]; General Anesthesia [PE]
5.4 ATC Code

N01AX10

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


N - Nervous system

N01 - Anesthetics

N01A - Anesthetics, general

N01AX - Other general anesthetics

N01AX10 - Propofol


5.5 Absorption, Distribution and Excretion

Absorption

Rapid - time to onset of unconsciousness is 15-30 seconds, due to rapid distribution from plasma to the CNS. Distribution is so rapid that peak plasma concentrations cannot be readily measured. Duration of action is 5-10 minutes.


Route of Elimination

It is chiefly eliminated by hepatic conjugation to inactive metabolites which are excreted by the kidney.


Volume of Distribution

60 L/kg [healthy adults]


Clearance

23 - 50 mL/kg/min

1.6 - 3.4 L/min [70 Kg adults]


The initial apparent volume of distribution is 13 to 76 L/kg.

MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 2467


Propofol is rapidly and extensively distributed in the body. It crosses the blood-brain barrier quickly, and its short duration of action is due to rapid redistribution from the CNS to other tissues, high metabolic clearance and high lipophilicity.

MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 2467


Approximately 70% of a dose is excreted in the urine within 24 hours after administration, and 90% is excreted within 5 days. Clearance of propofol ranges from 1.6 to 3.4 liters per minute in healthy 70 kg patients. As the age of the patient increases, total clearance of propofol may decrease. Clearance rates of 1.4 to 2.2 liters per minute in patients 18 to 35 years of age have been reported, in contrast to clearance rates of 1.0 to 1.8 liters per minute in patients 65 to 80 years of age.

MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 2467


The pharmacokinetics of propofol were best described by a three-compartment model. Weight was found to be a significant covariate for elimination clearance, the two intercompartmental clearances, and the volumes of the central compartment, the shallow peripheral compartment, and the deep peripheral compartment; power functions with exponents smaller than 1 yielded the best results. The estimates of these parameters for a 70-kg adult were 1.44 l/min, 2.25 l/min, 0.92 l/min, 9.3 l, 44.2 l, and 266 l, respectively. For patients older than 60 yr the elimination clearance decreased linearly. The volume of the central compartment decreased with age. For children, all parameters were increased when normalized to body weight. Venous data showed a decreased elimination clearance; bolus data were characterized by increases in the volumes of the central and shallow peripheral compartments and in the rapid distribution clearance (Cl2) and a decrease in the slow distribution clearance (Cl3). Pharmacokinetics of propofol can be well described by a three-compartment model. Inclusion of age and weight as covariates significantly improved the model. Adjusting pharmacokinetics to the individual patient should improve the precision of target-controlled infusion and may help to broaden the field of application for target-controlled infusion systems.

PMID:10719952 Schuttler J, Ihmsen H; Anesthesiology 92 (3): 727-38 (2000)


An iv dose of 14C-propofol (0.47 mg/kg) administered to 6 male volunteers was rapidly eliminated with 88% recovered in the urine in 5 days and <2% in feces. The dose was cleared by metabolism with <0.3% excreted unchanged. The major metabolites were the glucuronic acid conjugate of propofol and the glucuronic acid and sulfate conjugates of its hydroxylated derivative, 2,6-diisopropyl-1,4-quinol. Propofol glucuronide accounted for about 53% of the urinary radioactivity and was the major metabolite in plasma from 30 min post dose. The blood concentration of propofol declined in a biphasic manner from a maximum mean value of 0.44 ug/ml, 2 min after injection. The half-lives of the first and second exponential phases, mean values 5 min and 97 min respectively, varied widely among subjects. A proportion of the dose was cleared slowly, probably due to slow release from less well perfused tissues. Propofol accounted for 94% of the total blood radioactivity at 2 min but only about 6% from 3 to 8 hr post dose. Propofol has a volume of distribution equivalent to about 3 to 4 times body weight, and a mean total body clearance of 2.2 l/min.

PMID:3261062 Simons P, Cockshott I; Xenobiotica 18 (4): 429-40 (1988)


5.6 Metabolism/Metabolites

Hepatically metabolized mainly by glucuronidation at the C1-hydroxyl. Hydroxylation of the benzene ring to 4-hydroxypropofol may also occur via CYP2B6 and 2C9 with subsequent conjugation to sulfuric and/or glucuronic acid. Hydroxypropofol has approximately 1/3 of hypnotic activity of propofol.


Hepatic; rapidly undergoes glucuronide conjugation to inactive metabolites. An unidentified route of extrahepatic metabolism may also exist, suggested by the fact that propofol clearance exceeds estimated hepatic blood flow.

MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 2467


To determine the cytochrome P450 (CYP) isoforms involved in the oxidation of propofol by human liver microsomes. The rate constant calculated from the disappearance of propofol in an incubation mixture with human liver microsomes and recombinant human CYP isoforms was used as a measure of the rate of metabolism of propofol. The correlation of these rate constants with rates of metabolism of CYP isoform-selective substrates by liver microsomes, the effect of CYP isoform-selective chemical inhibitors and monoclonal antibodies on propofol metabolism by liver microsomes, and its metabolism by recombinant human CYP isoforms were examined. The mean rate constant of propofol metabolism by liver microsomes obtained from 6 individuals was 4.2 (95% confidence intervals 2.7, 5.7) nmol/min/mg protein. The rate constants of propofol by microsomes were significantly correlated with S-mephenytoin N-demethylation, a marker of CYP2B6 (r=0.93, P<0.0001), but not with the metabolic activities of other CYP isoform-selective substrates. Of the chemical inhibitors of CYP isoforms tested, orphenadrine, a CYP2B6 inhibitor, reduced the rate constant of propofol by liver microsomes by 38% (P<0.05), while other CYP isoform-selective inhibitors had no effects. Of the recombinant CYP isoforms screened, CYP2B6 produced the highest rate constant for propofol metabolism (197 nmol/min/nmol P450). An antibody against CYP2B6 inhibited the disappearance of propofol in liver microsomes by 74% /and SRP: reduced in vitro metabolism by blocking CYP 2B6/. Antibodies raised against other CYP isoforms had no effect on the metabolism of propofol. CYP2B6 is predominantly involved in the oxidation of propofol by human liver microsomes.

Oda Y, Hamaoka N; Br J Clin Pharmacol 51 (3): 281-5 (2001


Propofol has known human metabolites that include (2S,3S,4S,5R)-6-[2,6-Di(propan-2-yl)phenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid and 4-hydroxy-propofol.

S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560


5.7 Biological Half-Life

Initial distribution phase t1/2α=1.8-9.5 minutes. Second redistirubtion phase t1/2β=21-70 minutes. Terminal elimination phase t1/2γ=1.5-31 hours.


Terminal elimination half-life is 3 to 12 hours; prolonged administration may result in longer duration.

MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 2467


...The first-stage elimination half-life (t1/2 beta) of propofol /SRP: administered mixed with lidocaine/ in children was shorter (mean 9.3 +/- 3.8 (s.d.) min) than the values found in adults. This pharmacokinetic alteration may have clinical significance following repeated administration or continuous infusion of propofol.

PMID:2646847 Valtonen M, et al; Acta Anaesthesiol Scand 33 (2): 152-5 (1989)


An intravenous dose of 14C-propofol (0.47 mg/kg) /was/ administered to six male volunteers... . ...The half-lives of the first and second exponential phases, mean values 5 min and 97 min respectively, varied widely among subjects.

PMID:3261062 Simons P, Cockshott I; Xenobiotica 18 (4): 429-40 (1988)


5.8 Mechanism of Action

The action of propofol involves a positive modulation of the inhibitory function of the neurotransmitter gama-aminobutyric acid (GABA) through GABA-A receptors.


API SUPPLIERS

read-more
read-more

01

Bachem AG

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Flag Switzerland
Digital Content Digital Content
USDMF arrow-down Click Us! arrow-down
CEP/COS arrow-down JDMF arrow-down